Company Vical Incorporated Nasdaq
Equities
US9256021042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 15 | Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Prescription Therapeutics
100.0
%
| 7 | 100.0 % | 8 | 100.0 % | +15.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 7 | 100.0 % | 8 | 100.0 % | +15.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 20-11-30 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 20-06-30 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 20-11-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,973,306 | 5,877,545 ( 98.40 %) | 0 | 98.40 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FRTX Stock
- Stock
- Company Vical Incorporated